The prevalence of obesity in the pediatric population has increased in the last 2 decades and represents a serious health concern, with potential impact on outcomes of hematopoietic cell transplantation (HCT). We studied the effect of weight by age-adjusted body mass index (BMI) percentile in 1,281 pediatric patients (age 2-19 years) with severe aplastic anemia who underwent HCT between 1990 and. The study population was divided into 5 weight groups-underweight, risk of underweight, normal BMI range, risk of overweight, and overweight-according to age-adjusted BMI percentiles. Cox proportional hazards regression models for survival and acute graft-versus-host disease (aGVHD), performed using weight groups as the main effect and the normal BMI range (26th-75th percentile) as the baseline comparison, found higher mortality among overweight children (.95th percentile adjusted for age). Weight at transplantation did not increase the adjusted risk of grade III-IV aGVHD. The 1-year and 2-year overall survival rates were 60% and 59% for overweight children, compared with .70% in children with lower BMI at both time points (P \.001). Other significant factors associated with survival included race and region, donor type, conditioning regimens in related donor transplants, performance score, and year of transplantation. In conclusion, overweight children with aplastic anemia have worse outcomes after HCT. The impact of obesity on survival outcomes in children should be discussed during pretransplantation counseling.
INTRODUCTION
The childhood obesity problem has become epidemic in the United States and other industrialized countries. The percentage of obese children has doubled or tripled between the late 1970s and 2000, from approximately 5% to 15% in the United States, to 13 .2% in the western region of the European Union, and to 19.1% in the southern region of the European Union [1, 2] . This percentage remained stable from 2000 to 2006 in the United States, with 15.5% of children at or above the 95th percentile for body mass index (BMI) [3] .
Obese adults with malignant diseases experience more transplantation-related toxicity and worse overall and event-free survival compared with normalweight patients after autologous hematopoietic cell transplantation (HCT) [4] [5] [6] . Similar outcomes also have been observed after allogenic HCT in obese adults [7] . More recently, a large retrospective study demonstrated an increased risk of grade II-IV acute graft-versus-host disease (aGVHD) and infectious complications associated with obesity after transplantation [8] .
To date, few large-scale studies have addressed how undernutrition and overnutrition affect transplantation outcomes in the pediatric population. Compared with normal-weight children, underweight or obese children have worse survival rates after chemotherapy for leukemia [9, 10] . Data after transplantation are scarce, with 1 report demonstrating no impact of obesity on outcomes [7] .
The aim of the present study is to assess the effect of children's BMI on bone marrow transplantation outcomes. To best minimize potential confounders, such as including malignant disease where weight can be a surrogate of disease status at transplantation, intensity or recovery from previous treatments, and multiple types of conditioning regimens for different diseases, a population of patients with severe aplastic anemia (SAA) was selected.
PATIENTS AND METHODS

Data Sources
The Center for International Blood and Marrow Transplant Research (CIBMTR) is a voluntary working group of more than 450 transplantation centers worldwide that contribute detailed data on consecutive HCTs to a Statistical Center located at the Medical College of Wisconsin in Milwaukee and the National Marrow Program (NMDP) Coordinating Center in Minneapolis. Participating centers are required to report all transplantations consecutively; compliance is monitored by onsite audits. The CIBMTR maintains an extensive database of detailed patient-, transplant-, and disease-related information for transplantations performed worldwide and prospectively collects data longitudinally with yearly follow-ups. Computerized checks for discrepancies, physician review of submitted data, and onsite audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed in compliance with HIPAA regulations as a public health authority and also in compliance with all applicable federal regulations pertaining to the protection of human research participants, as determined by a continuous review by the Institutional Review Boards of NMDP and the Medical College of Wisconsin.
Patients
Our study population included pediatric patients aged 2-19 years who underwent a first allogeneic HCT for SAA between 1990 and 2005 reported to the CIBMTR. A total of 1,354 patients met the initial selection criteria. We excluded 37 patients from teams with inadequate follow-up or inconsistent reporting over the study period, to reduce selection and reporting bias of patients. This left 1,317 patients for inclusion in the analysis. Corrective action plan (CAP) modeling addresses the potential bias introduced by the exclusion of nonconsenting surviving patients by randomly excluding the same percentage of deceased patients using a weighted randomized scheme. This process is used to adjust for oversampling of dead patients in the consenting cohort [11] . CAP modeling in this dataset excluded an additional 37 unrelated donor patients. Our final study population included 860 HLA-matched siblings (Sibs) and 421 unrelated donor (URD) transplant recipients from 91 reporting centers worldwide.
Obesity has previously been defined based on BMI in adults. This index has been validated and shown to be of utility in children aged 2-19 years for predicting underweight, normal-weight, and overweight individuals [12, 13] . We divided the patients into 5 groups based on their age-adjusted BMI. Age-adjusted BMIs were calculated using 2000 Centers for Disease Control and Prevention (CDC) BMI-for-age growth charts to obtain percentile rankings, which were then used as an indicator to assess the BMI of the study population with reference to the general population [14, 15] . Weight categories were defined as follows: underweight, \5th percentile (n 5 109); at risk for underweight, 5th percentile to \25th percentile (n 5 196); normal weight, 25th percentile to 75th percentile (n 5 527); at risk for overweight, 76th percentile to 95th percentile (n 5 306); and overweight, .95th percentile (n 5 143). The sample size of this cohort allowed us to include patients in the threshold percentiles by adding groups at risk for underweight and overweight, which could demonstrate a possible dose-effect relationship of BMI and outcome.
Follow-up was updated for all patients in the data file. Each patient enrolled in the study had a minimum of 2 years of potential follow-up.
Study Endpoints and Variables
Primary endpoints were 100-day mortality, aGVHD grade III-IV, and overall survival (OS), with 100-day mortality defined as death from any cause on or before day 100 posttransplantation. Patients alive at last observation with fewer than 100 days of follow-up were not considered at risk for this event. aGVHD grade III-IV was defined using the Glucksberg system, which grades GVHD based on the pattern and severity of abnormalities in skin, gastrointestinal system, and liver [16] . This event was summarized by the cumulative incidence estimate, with death and second transplantation as competing risks. OS was defined as time to death from any cause; surviving patients were censored at time of last follow-up.
Variables selected for analysis included age (2-5 vs 6-10 vs 11-15 vs 16-19 years), Lansky performance score ($90 vs \90 vs missing), donor-recipient cytomegalovirus (CMV) serology, race and ethnicity, country or region, number of transfusions before transplantation (\20, 20-50, or .50 units), time from diagnosis to transplantation (\6 months vs $6 months), donor type and HLA matching (Sibs vs URD matched, URD partially matched, and URD mismatched, according to Weisdorf et al. [17] ), conditioning regimen (separately by donor type), year of transplantation (1990-1993 vs 1994-1997, 1998-2001, and 2002-2005) , and GVHD prophylaxis (cyclosporine/methotrexate vs T cell depletion, cyclosporine 6 other, and tacrolimus 6 other). Because the selection of conditioning regimens varied depending on type of donor, conditioning regimens used in Sibs and URD transplants were analyzed separately.
Statistical Analysis
Variables related to patient, disease, and transplant characteristics were compared using the c 2 test for categorical variables and the Kruskal-Wallis test for continuous variables. A P value of\.05 was considered significant for differences among weight groups. Univariate probabilities for OS and 100-day mortality were calculated using the Kaplan-Meier estimator. The univariate probability of aGVHD III-IV was calculated using the cumulative incidence function, with death as the competing risk [18] .
In the multivariate analysis, a forward stepwise Cox proportional hazards model was used to select covariates for inclusion in the model [19] . Because the primary objective was to compare the BMI percentile groups (main effect), we forced BMI into the main model while selecting other covariates that might affect that particular outcome. Models for OS and aGVHD III-IV were fitted for URD and HLA-identical sibling donors separately and then combined because of their similar effects of baseline weight on outcomes. Conditioning regimen was analyzed separately by donor type. Patient region and race were entered into the models as interaction terms for patients who underwent transplantation in the United States and South America with available race/ethnicity information. All variables were examined to ensure that they complied with the proportional hazards assumption, and interactions with the main effect were tested in the model. Comparison across 5 distinct groups as the main effect required adjustments for multiple comparisons. Bonferroni corrections were applied to allow adjustment for multiple comparisons between each weight group and the normal weight group. Thus, a P value \.0167 was considered statistically significant, whereas the P values for inclusion in the final models of all other potentially confounding covariates were set at \.05. All analyses were performed using SAS 9.2 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
A total of 1,281 patients were included in the analysis. The number of patients in each weight category was as follows: underweight, 109 (8.5%); at risk for underweight, 196 (15.3%); normal weight, 527 (41.1%); at risk for overweight, 306 (23.8%); overweight, 143 (11.1%). Patient characteristics are compared by weight group in Table 1 and by donor type in Table  2 . Obese patients more frequently received an URD graft (18% URD vs 8% Sibs) and underwent transplantation in the United States (60%). Underweight and at risk for underweight patients were older than patients in the other weight groups (P \ .01), and 66% of patients in these weight groups were from Europe, the Middle East, and South America. The distribution of Lansky performance scores at transplantation, previous transfusions, and time from diagnosis to transplantation did not differ among weight groups. URD transplants were performed more commonly after 1998. Compared with Sibs recipients, URD recipients were more likely to undergo transplantation after 6 months from diagnosis and to receive total body irradiation (TBI)-containing regimens.
Busulfan-containing regimens were used mostly in HLA-matched donor transplantations from centers outside the United States. Antithymocyte globulin (ATG) was commonly used for both Sibs and URD transplants, and cyclosporine and methotrexate were the most common GVHD prophylaxis treatments, used in 81% of Sibs transplants and in 50% of URD transplants.
Acute GVHD
The probability of aGVHD III-IV at day 100 was 8% (95% confidence interval [CI], 4%-14%] for underweight patients, 8% (95% CI, 5%-13%) for at risk of underweight patients, 11% (95% CI, 8%-14%) for normal-weight patients, 15% (95% CI, 11%-19%) for at risk of overweight patients, and 24% (95% CI, 18%-32%) for overweight patients (P \ .01). Multivariate analysis of aGVHD III-IV adjusted for significant covariates-race/ethnicity/region, donor type, HLA matching, conditioning regimen (Sibs only), and GVHD prophylaxis-resulted in a relative risk (RR) of 1.55 (95% CI, 1.00-2.41; P 5 .05) for the overweight group compared with the normal-weight group. The overall P value for BMI in the aGVHD III-IV model was .15. The varying impacts of significant covariates on the development of aGVHD III-IV are summarized in Table 3 . It is noteworthy that a reduced risk of aGVHD III-IV was seen in children undergoing transplantation in Asia (RR, 0.18; 95% CI, 0.06-0.61; P \ .01) compared with Caucasian children in the United States; and also in recipients of T cell-depleted grafts (RR, 0.32; 95% CI, 0.18-0.54; P \ .01) compared with recipients conditioned with cyclosporine/methotrexate. The risk for aGVHD III-IV was increased in URD recipients compared with Sibs recipients regardless of HLA matching (Table 3) . Among Sibs recipients, the risk was greater in those receiving a busulfancontaining regimen compared with those receiving a cyclophosphamide and ATG combination (RR, 4.75; 95% CI, 1.88-12.02; P \ .01).
Survival Outcomes
Mortality at 100 days posttransplantation was 13% (95% CI, 7-20) for underweight patients, 15% (95% CI, 10%-20%) for at risk of underweight patients, 12% (95% CI, 9%-14%) for normal-weight patients, 17% (95% CI, 13%-21%) for at risk of overweight patients, and 29% (95% CI, 22%-37%) for overweight patients (P \ .01). Adjusted survival curves according to weight group are summarized in Figure 1 . Multivariate analysis of mortality, which was adjusted for race/ethnicity/region, donor type, HLA matching, conditioning regimen (Sibs only), Lansky performance score, and years after transplantation, resulted in an RR of death of 1.71 (95% CI, 1.24-2.35; P \. 01) in overweight patients compared with normal-weight patients. Figure 2 summarizes the magnitude of the effect of weight on mortality across all groups.
The different impacts of significant covariates on mortality are summarized in Table 3 . It is noteworthy that reduced mortality was observed in patients who underwent transplantation between 2002 and 2005 compared with those who underwent transplantation between 1990 and 1993 (RR, 0.44; 95% CI, 0.29-0.66; P \ .01). Increased mortality was observed in AfricanAmerican recipients compared with Caucasian recipients in the United States (RR, 1.84; 95% CI, 1.17-2.91; P \ .01). Recipients of URD, regardless of HLA matching (Table 3) , and patients with Lansky performance score of\90 at the time of transplantation (RR, 1.71; 95% CI, 1.36-2.14; P \ .01). Mortality was higher with Bu-containing conditioning regimens compared to cyclophosphamide/ATG, among recipients of Sibs grafts (RR, 3.13; 95% CI. 1.85-5.29, P \ 0.01).
Causes of Death
A total of 363 patients died during the course of the study: 204 URD recipients (48%) and 159 Sibs recipients (18%). The attributed causes of death reported by transplant centers were infection (24%), graft failure (18%), organ failure (17%), GVHD (14%), idiopathic pneumonia syndrome (12%), hemorrhage (9%), posttransplantation cancer (2%), and unknown causes (4%). The most common cause of death was infection in URD recipients (n 5 52; 25%), and graft failure in Sibs recipients (n 5 37; 23%).
DISCUSSION
Our data show that overweight children (age-adjusted BMI .95th percentile) with SAA experienced worse survival outcomes after allogeneic HCT compared with other children with SAA. This finding demonstrates that obesity in this homogenous population has a significant negative impact on survival and possibly also on complications post-HCT. Overweight children with SAA have no apparent increase in the rate of aGVHD III-IV.
The effect of body weight on transplantation outcome has been the topic of several studies, with results varying depending on the indication for transplantation, type of transplant, and patient population. This question was initially addressed in recipients of autologous HCT for malignant diseases. Obese adults, defined according to BMI, demonstrate higher mortality after autologous HCT for non-Hodgkin lymphoma and acute myelogenous leukemia (AML) [4, 6] . Subsequent studies using the CIBMTR database addressed this question in 4,681 adult recipients of autologous HCT for lymphoma. Obese patients experienced similar survival outcomes as overweight and normal-weight patients. Transplantation-related mortality was 2.5-fold greater for underweight patients compared with all other weight groups [5] . Similar results (ie, comparable survival outcomes of obese and nonobese patients and shortened survival in underweight patients) were found in patients with AML receiving HCT [20] . Despite these observations in a large cohort of patients, obesity was identified as an independent prognostic factor for nonrelapse mortality after HCT and is a component of the HCT Comorbidity Index [21] .
The results from obesity studies in the adult population might not apply directly to children. The definition of obesity in adults uses a single BMI measurement at the time of transplantation. In children, age adjustments are needed for defining weight groups, and whether BMI in adults and age-adjusted BMI in children have the same prognostic impact is uncertain. Chemotherapy dose adjustments based on weight to minimize toxicity are likely to differ between children and adults [10] . Children with leukemia at the opposite ends of the weight scale, overweight and underweight, have higher mortality during standard chemotherapy induction treatments [9, 10] . Studies on the impact of weight on posttransplantation outcomes in the pediatric population are scant. One single-institution study analyzed 54 children with BMI $ 95th percentile among a cohort of 325 recipients of allogeneic HCT for treatment of several diseases and found a 5-year OS probability of 47% in the overweight group and 70% in the non-overweight group (P 5 .02) [22] .
The effect of obesity on aGVHD is less clear. Our univariate analysis demonstrated a higher rate of aGVHD III-IV in the overweight group, which was likely related to the higher proportion of URD recipients in this group. After adjusting the analysis for donor type and other variables, this effect of weight and aGVHD III-IV disappeared.
A Japanese study of patients of all ages with malignant diseases also found a strong relationship between GVHD and weight at time of transplantation [8] .
Although in that study, univariate analysis demonstrated a strong association between weight and both aGVHD and chronic GVHD, this association disappeared in multivariate analysis. In our analysis, other factors were strongly associated with development of aGVHD III-IV in patients with SAA. As expected, URD recipients and HLA disparity were associated with higher rates of aGVHD III-IV. Recipients from Asia experienced less frequent aGVHD III-IV, which could be attributed to lower rates of aGVHD in URD recipients in Asia due to less HLA gene variability in that region.
Race and region also were associated with survival outcome. Interestingly, mortality was higher in African-American children compared with Caucasian children in the United States. No data on socioeconomic status, which could affect outcomes along with access to care, were collected for these patients. Improved survival outcomes in the later periods are attributed to improvements in donor and patient selection, as has been described in previous studies [23] . The effect of conditioning regimen was analyzed separately in Sibs recipients and URD recipients. The use of busulfan in Sibs recipients was associated with worse survival. No effect of conditioning regimen and or of survival outcome was seen in URD recipients.
The present study is the largest study to date conducted to assess the effect of weight on outcomes of allogeneic HCT in children with SAA. Nonetheless, this is a retrospective study, using registry data spanning a 15-year period. The decision to proceed to transplantation was made by individual transplant physicians as part of center-specific protocols or as a standard of care. Despite the large number of cases, some variables (eg, dose-adjustment practices and detailed previous treatment, including transfusion) were not present in all patients and could not be formally examined. Another limitation of this study was the definition of obesity. The weight charts in which the age-adjusted BMIs were calculated are normalized to the US population, but the study used children outside the United States as well. This might explain the higher number of patients from Asia, South America, and Europe in the underweight groups, which could clarify why this group did not experience poorer survival rates, as has been shown in other studies of underweight children. Small numbers of underweight children in the United States did not allow for a meaningful subset analysis to address this question.
In conclusion, our study indicates that obese children with SAA have a higher mortality rate after allogeneic HCT compared with normal-weight children. There was no impact of weight on the development of aGVHD III-IV in this population. Obesity is not an easily modifiable risk factor, and optimizing nutrition and weight pretransplantation is difficult due to the urgency of the procedure. The impact of obesity on transplantation outcomes for this disease should be discussed during pretransplantation counseling. Prospective studies with a better definition of obesity, using anthropometrics in children, are important to gaining more insight into the association between obesity and posttransplantation outcomes.
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